Frontlight ResearchEarly access
Not yet taking people in SwedenPhase 1
CellThRPE1 study in people with geographic atrophy from dry macular degeneration
Tests the CellThRPE1 treatment in adults with geographic atrophy from dry macular degeneration.
Key facts
- Who runs it
- St Erik Eye Hospital
- Where
- Solna, SwedenSee the site
- Trial code
- Registry title
- CellThRPE1
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 15 people, planned
- Started
- 2 May 2025
- Expected to end
- 2 Aug 2032
- Type of study
- Interventional
- Record updated
- 5 June 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with geographic atrophy caused by dry age-related macular degeneration.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Geographic atrophy secondary to dry age-related macular degeneration
Where in Sweden
- St Erik Eye HospitalSolna, SwedenNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- CellThRPE1 study in people with geographic atrophy from dry macular degenerationGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 5 June 2025